Legal
Acceptable Use Policy
This Acceptable Use Policy (this "Policy") governs Customer’s use of the Service provided by Auxfield Labs, Inc. ("ALI"). This Policy is incorporated into and forms part of the Qiviut Terms of Service (the "Terms"). Capitalized terms used but not defined in this Policy, including "Service," have the meanings given in the Terms.
Violation of this Policy is a material breach of the Terms. Violations designated below as zero-tolerance violations permit ALI to suspend or terminate Customer’s Account immediately and without a cure period.
1. BIOSECURITY AND PROHIBITED BIOLOGICAL APPLICATIONS
The following are zero-tolerance violations. Customer will not use the Service, any Computation, or any Output to:
- (a) design, develop, engineer, optimize, enhance, synthesize, produce, or acquire any biological, chemical, radiological, or nuclear weapon, or any delivery system for one;
- (b) design, modify, enhance, or optimize any toxin, pathogen, virus, prion, or other biological agent to increase its virulence, transmissibility, environmental stability, host range, lethality, resistance to therapeutics or vaccines, or capacity to evade detection or immune response;
- (c) submit any Input in, or use any Output for, work involving any biological agent or toxin listed on the United States Select Agents and Toxins List maintained under 42 C.F.R. Part 73, 7 C.F.R. Part 331, or 9 C.F.R. Part 121, or on any equivalent list of any other jurisdiction. This restriction applies whether or not Customer holds a registration, license, or approval for that work, and whatever the purpose of the work. Work involving a listed agent or toxin may be conducted on the Service only under a separate written agreement signed by ALI, which ALI may grant or withhold in its discretion;
- (d) design or develop any agent intended to cause harm to human, animal, or plant populations, or to damage crops, livestock, food supplies, or ecosystems;
- (e) design, develop, or optimize any compound or biological agent intended for use as a chemical or biological weapon, including nerve agents, blister agents, and incapacitating agents;
- (f) circumvent, evade, defeat, or test the limits of any biosecurity screening, nucleic acid synthesis screening, biosafety control, or export control measure, including by fragmenting, obfuscating, or otherwise structuring Inputs or Outputs to avoid detection by any such measure; or
- (g) design, develop, or optimize any agent or compound for the purpose of disabling, degrading, or defeating a therapeutic, vaccine, diagnostic, or biosecurity countermeasure. This clause (g) does not prohibit research undertaken to understand, predict, detect, or mitigate resistance, immune escape, or countermeasure failure, including the development of improved therapeutics, vaccines, and diagnostics, which Section 7 of this Policy permits.
Customer will conduct its work under the Service in accordance with all biosafety and biosecurity requirements applicable to it, including any United States Government policy on dual use research of concern, gain-of-function research, or high-risk life sciences research, as in effect from time to time, and any equivalent requirements of any other jurisdiction. Customer is responsible for determining which of those requirements apply to it.
2. WEAPONS AND MILITARY APPLICATIONS
The following are zero-tolerance violations. Customer will not use the Service, any Computation, or any Output:
- (a) in the design, development, testing, production, maintenance, or deployment of any weapon or weapons system, including any munition, ordnance, or directed-energy weapon;
- (b) for military targeting, combat operations, or the selection or engagement of targets;
- (c) for the development of any autonomous weapons system or any system that selects or engages targets without meaningful human control; or
- (d) for any activity requiring authorization under the International Traffic in Arms Regulations, or for any other defense article or defense service as defined under those regulations.
Research conducted by or for a governmental defense or security agency that is not within clauses (a) through (d) is not prohibited by this Section 2, but Customer remains responsible for compliance with Section 3 of this Policy and with all applicable law.
3. EXPORT CONTROL AND SANCTIONS
The following are zero-tolerance violations. Customer will not:
- (a) access or use the Service from, or make the Service or any Output available in, any country or territory that is subject to comprehensive United States economic sanctions or embargo, as designated by the United States Department of the Treasury’s Office of Foreign Assets Control from time to time, which as at the effective date of this Policy are Cuba, Iran, North Korea, and the Crimea, Donetsk, and Luhansk regions of Ukraine;
- (b) provide access to the Service, or provide any Output, to any person identified on the United States Department of the Treasury’s Specially Designated Nationals and Blocked Persons List, the United States Department of Commerce’s Denied Persons, Entity, or Unverified Lists, or any similar restricted party list maintained by any jurisdiction whose laws apply to Customer;
- (c) use the Service or any Output for any end use prohibited by the Export Administration Regulations, including any prohibited nuclear, missile technology, chemical weapons, or biological weapons end use; or
- (d) use the Service or any Output in a manner that would cause ALI to violate any export control, sanctions, or anti-boycott law.
Separately from the restrictions above, and as a matter of its own business policy rather than as a statement of any government requirement, ALI declines to open or maintain an Account for a person located in Syria, and may do the same for any other country or territory that ALI identifies on the page where this Policy is posted. Syria is not subject to comprehensive United States sanctions, and its inclusion here is ALI's own commercial decision. ALI determines the country from which an Account is registered, and Paddle screens the purchaser of any Credit pack against restricted party lists as part of its own processes. Determining a country of registration is not restricted party screening, and ALI does not screen the identity of the holder of an Account that makes no purchase.
4. UNLAWFUL AND HARMFUL USE
Customer will not use the Service:
- (a) in violation of any applicable law, regulation, or governmental order;
- (b) to infringe, misappropriate, or violate the intellectual property, privacy, publicity, or other rights of any person;
- (c) to submit any Input that Customer does not have the right to submit, or that Customer does not have the right to have transmitted to the Public Reference Services as described in Section 5.5 of the Terms, including any Input subject to a third party’s confidentiality obligation or material transfer agreement that prohibits its submission or that transmission;
- (d) to submit any prohibited Input described in Section 5.4 of the Terms, including personally identifiable human genetic or genomic data and protected health information; or
- (e) in furtherance of any fraud, misrepresentation, or deceptive practice, including the fabrication or misrepresentation of research results.
5. TECHNICAL AND SECURITY RESTRICTIONS
Customer will not:
- (a) share, publish, transfer, or expose any API Key other than to Permitted Users as permitted by Section 3.2 of the Terms, or embed any API Key in any publicly distributed software, repository, container image, or client application;
- (b) exceed, circumvent, or attempt to circumvent any rate limit, quota, concurrency limit, or other technical restriction, including by distributing Requests across multiple Accounts or credentials;
- (c) register or maintain multiple Accounts to obtain additional Free Credits or repeated Monthly Top-Ups, to evade a suspension or termination, or to circumvent any limit under the Terms;
- (d) access or attempt to access any endpoint, server, interface, or system operated by or for ALI other than the API, the Account interface, and any other interface that ALI publishes in the Documentation as available for Customer use, including any endpoint used for benchmarking, evaluation, testing, or internal purposes, whether or not that endpoint is technically reachable or protected by authentication;
- (e) probe, scan, or test the vulnerability of the Service or any ALI system, breach or circumvent any authentication or security measure, or attempt to gain unauthorized access to any Account, system, or data;
- (f) introduce into the Service any virus, worm, malicious code, or other harmful component, or interfere with or disrupt the integrity, performance, or availability of the Service or the data of any other customer;
- (g) use any automated means to scrape, index, or harvest the Service or the Documentation, other than ordinary programmatic use of the API in accordance with the Documentation; or
- (h) remove, obscure, or alter any proprietary notice appearing in or on the Service or the Documentation, or remove or alter any attribution required by a third-party license identified under Section 6.8 of the Terms. This clause (h) does not restrict Customer's rights to modify, distribute, publish, and commercialize its Outputs under Section 6 of the Terms.
Clauses (d), (e), and (h) of this Section 5 correspond to Sections 4.4, 7.2(e), and 7.2(d) of the Terms. A breach of any of them permits ALI to terminate without a cure period under Section 15.3(b) of the Terms, whether or not this Policy designates it a zero-tolerance violation.
6. PROTECTION OF ALI TECHNOLOGY
The following are zero-tolerance violations. Customer will not:
- (a) reverse engineer, decompile, disassemble, or otherwise attempt to derive the source code, architecture, algorithms, computational methods, model parameters, or trade secrets of MuskOx, Qiviut, or any other ALI Technology, except to the extent this restriction is unenforceable under applicable law;
- (b) submit Requests in a systematic, automated, or high-volume pattern designed or reasonably likely to extract, replicate, approximate, distill, or reverse-derive MuskOx, Qiviut, or any computational method they embody;
- (c) use the Service, any Output, or any information obtained from either to develop, train, or improve any product or service that is competitive with MuskOx, Qiviut, or the Service, subject to the proviso in Section 7.2(c) of the Terms; or
- (d) without ALI’s prior written permission, incorporate the API, the Service, or any call to either into any product, application, platform, or service that Customer makes available to any third party, or resell, sublicense, rent, lease, distribute, or otherwise provide access to the API, the Service, or any API Key to any third party other than Permitted Users as permitted by Sections 3.2 and 4.1 of the Terms.
For clarity, nothing in this Section 6 restricts Customer’s rights in its Outputs under Section 6 of the Terms, including the right to use, publish, and commercialize Outputs and to deliver Outputs to clients and collaborators as permitted by Sections 5.3 and 6.3 of the Terms.
7. PERMITTED USES
For the avoidance of doubt, and subject to the remainder of this Policy and to the Terms, the following uses are permitted:
- (a) commercial drug discovery and development research, including target identification, lead optimization, and structure-based drug design;
- (b) protein engineering and enzyme design for industrial, agricultural, environmental, and therapeutic purposes;
- (c) academic and nonprofit research, including research published in the scientific literature;
- (d) research undertaken to understand, predict, detect, or mitigate therapeutic resistance, immune escape, or countermeasure failure, including the development of improved therapeutics, vaccines, and diagnostics;
- (e) the performance of Computations on behalf of Customer’s own clients and the delivery of the resulting Outputs to those clients, as permitted by Section 5.3 of the Terms;
- (f) the commercialization of Outputs, including Outputs obtained using Free Credits, and of any compound, molecule, product, method, discovery, publication, or intellectual property developed using Outputs; and
- (g) publication of Customer’s own evaluation or benchmarking of the Service in accordance with Section 7.3 of the Terms.
8. MONITORING AND ENFORCEMENT
8.1 Monitoring and Review. ALI may monitor Account activity, Request metadata, and usage patterns. ALI reserves the right to examine Inputs and Outputs by automated means, including to detect conduct prohibited by Sections 1, 2, and 3, and to hold, decline, or halt any Computation on the basis of that examination. A member of ALI's staff may open the content of an Input or Output only where ALI has a reasonable basis to suspect a violation of this Policy, where it is necessary to investigate a technical fault, where Customer has requested or authorized it, or where a legal request requires it, in each case for the purposes permitted by Section 10.4 of the Terms, with a recorded reason and a logged access. A Computation that is held or declined consumes no Credits, as provided in Section 8.3 of the Terms; a Computation that is released after review and delivers an Output is charged in the ordinary way. ALI has no obligation to monitor, examine, review, or screen any Input, does not represent that any Input is reviewed or screened, and nothing ALI does under this Section relieves Customer of responsibility for compliance with this Policy.
8.2 Investigation. Customer will cooperate in good faith with any reasonable investigation by ALI of a suspected violation of this Policy, including by providing information about the purpose and context of the Requests in question.
8.3 Enforcement. ALI may suspend Customer’s access under Section 4.6 of the Terms, and may terminate under Section 15.3 of the Terms, for any violation of this Policy. A Computation may be held or declined automatically on the basis of the examination described in Section 8.1. An Account is not suspended automatically on the basis of that examination: a suspension on those grounds is decided by a member of ALI's staff, with a reason that is stated and recorded. This Section does not affect a suspension arising from a chargeback or payment dispute under Section 9.5 of the Terms. For a zero-tolerance violation, ALI may suspend and terminate immediately and without a cure period. ALI will give notice of a suspension as soon as reasonably practicable, except that ALI may withhold or delay notice as provided in Section 4.6 of the Terms.
8.4 Reporting to Authorities. ALI may report a suspected violation of this Policy, and may disclose Account information, Request metadata, Inputs, and Outputs to law enforcement, regulatory, biosecurity, public health, or export control authorities, in each case in accordance with and subject to the limits in Sections 10.7 and 10.8 of the Terms.
8.5 Credits on Termination. If ALI terminates Customer’s Account for a violation of this Policy, the treatment of Customer’s unused Credits is governed by Section 15.4 of the Terms. Unused Free Credits are forfeited; unused Purchased Credits are refunded, calculated as provided in Section 2.2 of the Refund Policy, less any amount ALI is entitled to recover from Customer, and except where a refund is prohibited by applicable law, including sanctions law.
8.6 Reporting Violations. Suspected violations of this Policy may be reported to ALI at hello@auxfield.com.
9. CHANGES TO THIS POLICY
ALI may update this Policy from time to time by posting an updated version with a new version number and effective date. A change that materially expands the categories of prohibited use, or that otherwise materially reduces Customer’s rights, takes effect in accordance with Sections 18.1, 18.2, and 18.4 of the Terms. Other changes, including clarifications, take effect when posted. A change that ALI is required by law to make takes effect on the date the law requires, and ALI will give as much notice as the law allows; where such a change is material, Sections 18.1 and 18.2 of the Terms apply to the extent they are consistent with that requirement. Continued use of the Service after a change takes effect constitutes acceptance of the updated Policy, except where Section 18.2 of the Terms requires Customer’s acceptance.